Loading
CHD4 (ATP-dependent chromatin remodeler CHD4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer, Colorectal cancer, Renal cell carcinoma and 5 more.
ATP-dependent chromatin-remodeling factor that binds and distorts nucleosomal DNA. Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin. Localises to acetylated damaged chromatin in a ZMYND8-dependent manner, to promote transcriptional repression and double-strand break repair by homologous recombination.
Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.28, genetic association 0.00, somatic mutation 0.95). IntOGen calls it a driver in 9 cohorts (6 activating, 3 loss-of-function), covering Acute Lymphoblastic Leukaemia, Renal Clear Cell Carcinoma, Colon Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Neuroblastoma, Endometrial Carcinoma and others.
In plain words · CHD4 (ATP-dependent chromatin remodeler CHD4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer, Colorectal cancer, Renal cell carcinoma and 5 more.
CHD4 (ATP-dependent chromatin remodeler CHD4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Endometrial cancer, Colorectal cancer, Renal cell carcinoma and 5 more.
ATP-dependent chromatin-remodeling factor that binds and distorts nucleosomal DNA. Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin.
No product in this corpus aims at CHD4 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1995. Earliest sequence paper UniProt cites for the protein: Seelig H.P. et al, Arthritis Rheum, 1995, "The major dermatomyositis specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation". Source.
Sources: HGNC HGNC:1919 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14839 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000111642 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: colorectal cancer 0.57, gastric cancer 0.52, endometrial cancer 0.55, melanoma 0.52, skin cancer 0.53 (GraphQL API, CC0)); IntOGen CHD4 (driver in 9 cohorts (Act 6, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
ATP-dependent chromatin-remodeling factor that binds and distorts nucleosomal DNA. Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin. Localises to acetylated damaged chromatin in a ZMYND8-dependent manner, to promote transcriptional repression and double-strand break repair by homologous recombination. Involved in neurogenesis. Location: Nucleus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome (UniProt). Locus 12p13.31 (HGNC).
Query for this target: (TITLE:"CHD4" OR ABSTRACT:"CHD4" OR TITLE:"chromodomain helicase DNA binding protein 4" OR ABSTRACT:"chromodomain helicase DNA binding protein 4" OR TITLE:"ATP-dependent chromatin remodeler CHD4" OR ABSTRACT:"ATP-dependent chromatin remodeler CHD4" OR TITLE:"Mi-2b" OR ABSTRACT:"Mi-2b" OR TITLE:"Mi2-BETA" OR ABSTRACT:"Mi2-BETA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CHD4, not a curated reading list.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.
Shares Clear cell renal cell carcinoma, Endometrial cancer, Renal cell carcinoma, IntOGen.